$XBI $89.80 | +0.9%
Pipeline Updates
$RETA +2.2% Reata Pharmaceuticals Receives Complete Response Letter From The FDA for Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome. source
$MYOV+4.2% Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX® (relugolix) for the Treatment of Advanced Prostate Cancer. source
$VBIV 0% VBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine for Immunization Against Hepatitis B Infection in Adults in the European Union. source
$CLVS +4.1% Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study And Multi-Tumor Imaging Investigator-Initiated Trial Of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate At An Upcoming Nuclear Medicine Meeting. source
$TGTX +0.6% TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum. source
$CARA +3.1% Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients. source
$AQST +12.1% Aquestive Therapeutics Reports Positive Topline Data From Part 1 Of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film. source
$BHVN -8.9% BIOHAVEN AND PFIZER RECEIVE POSITIVE CHMP OPINION FOR MIGRAINE TREATMENT. BIOHAVEN ACQUIRES KV7 ION CHANNEL PLATFORM FOR THE TREATMENT OF EPILEPSY AND OTHER NEUROLOGIC DISORDERS FROM CHANNEL BIOSCIENCES, A SUBSIDIARY OF KNOPP BIOSCIENCES. BIOHAVEN LICENSES TALDEFGROBEP ALFA, A PHASE 3-READY ANTI-MYOSTATIN ADNECTIN FOR SPINAL MUSCULAR ATROPHY (SMA), FROM BRISTOL MYERS SQUIBB. source
$IMCR -0.7% Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma. source
Posted by DV/FS
Comments